High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (COLDSTER).

Authors: Dhooria S, Chaudhary S, Sehgal IS, Agarwal R, Arora S

PMID: 34887325 PMCID: PMC8850687 DOI: 10.1183/13993003.02930-2021

Abstract

High-dose prednisolone may not be superior to a low-dose 6-week regimen in improving clinical, physiological and radiological outcomes, or health-related quality of life, in patients with symptomatic post-COVID-19 diffuse parenchymal lung abnormalities.

Keywords: prednisolone, Long COVID, COVID-19

Source: https://pubmed.ncbi.nlm.nih.gov/34887325/
Archive: https://archive.is/heIqQ